FDA To Assess Anemia Drug Risks In Kidney Patients

Law360, New York (October 15, 2010, 10:59 AM EDT) -- A U.S. Food and Drug Administration advisory panel will meet on Monday to evaluate chronic kidney disease patients' use of popular anemia drugs made by Johnson & Johnson and Amgen Inc. and consider possible labeling and dosage changes, in light of new concerns about the drugs' health risks.

The purpose of the meeting, according to a draft briefing memo released Thursday, is to seek the advice of committee members on the benefit risk profile of eythropoiesis-stimulating agents, based on recent clinical test results that showed the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.